UK starts H5N1 human vaccine trial

Bird-flu vaccines for people are now a real UK clinical trial, not just a preparedness memo. In late April, researchers gave the first UK dose of Moderna’s mRNA-1018, an experimental A(H5) influenza vaccine built for pandemic-threat strains like H5N1. The point is not that Britain suddenly has human bird flu spreading. It does not. The point is that health officials want data in hand before that changes. ### What actually started? A phase 3 trial started in the UK and the US, with around 4,000 adult volunteers overall and about 3,000 of them expected to be recruited in the UK. NIHR said the first UK dose had already been delivered by April 22, 2026, and the study is being run through 26 UK sites. Moderna sponsors the trial, while the UK side sits inside its government partnership managed by UKHSA. (nihr.ac.uk) ### Who are they trying to vaccinate? This is not a mass-rollout rehearsal for the whole public. The trial is prioritising people more likely to encounter the virus — especially poultry workers and adults over 65. That tells you what the study is really for: testing a practical pre-pandemic vaccine strategy in groups who might need protection first if spillover risk rises. (nihr.ac.uk) ### What is the vaccine? mRNA-1018 is an mRNA vaccine candidate. Basically, it gives cells instructions to make a viral protein so the immune system can practice on a harmless stand-in instead of the live virus. If that sounds familiar, it should — it uses the same broad platform idea that made the COVID mRNA shots possible, with lipid nanoparticles acting as the delivery vehicle. (sciencemediacentre.org) ### Why H5N1, specifically? H5N1 is still mainly a disease of birds, but that is exactly why it worries pandemic planners. It has spread widely in wild birds and poultry, and in recent years it has also turned up in more mammal species, including cattle in the US. Human infections remain rare and are usually tied to close contact with infected animals, but every jump into a new host is another chance for the virus to adapt. (nihr.ac.uk) ### Is this because the UK thinks a pandemic has started? No — and that distinction matters. UKHSA has been clear that there is no evidence of sustained human-to-human spread that would trigger use of an H5 vaccine stockpile. This trial is about preparedness: generating safety and immune-response data now, so officials are not starting from zero if the risk picture worsens later. (ukhsa.blog.gov.uk) ### Didn’t the UK already buy H5 vaccine doses? Yes. In December 2024, the UK secured a contract for more than 5 million doses of a human H5 influenza vaccine from CSL Seqirus as part of pandemic planning. That stockpile move and this Moderna trial are related but different. One gives the country doses it could deploy in an emergency. The other tests a newer mRNA candidate that might broaden future options. (gov.uk) ### Is this the same as the bird vaccine trial? No. In March 2026, the UK also started avian-influenza vaccine trials in turkeys in England. That work is about protecting poultry, disease control, and trade. The human trial is about whether an H5 vaccine can safely generate useful immunity in people. Same virus family, different problem. (gov.uk) ### So what’s the real significance? The big shift is that Britain has moved from stockpiling and planning into live human testing of an H5 pandemic vaccine at scale. That does not mean H5N1 is about to become the next COVID. But it does mean officials think the risk is serious enough to practice before the fire starts. (nihr.ac.uk) (gov.uk)